Evidence map›Paper›PMID 38564595›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer.

Yoo Jane Han, Siyao Liu, Ashley Hardeman, Padma Sheila Rajagopal, Jeffrey Mueller, Galina Khramtsova, Ayodele Sanni, Mustapha Ajani, Wendy Clayton, Ian W Hurley and 5 more

Open access · greenAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Multi-omics exploration of hypoxia in gastric cancer.World journal of surgical oncology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Yoo Jane Han *Center for Clinical Cancer Genetics and Global Health, Department of Medicine, University of Chicago, Chicago, Illinois.ORCID 0000-0002-7465-2680
Siyao Liu *Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-7919-9184
Ashley Hardeman *Center for Clinical Cancer Genetics and Global Health, Department of Medicine, University of Chicago, Chicago, Illinois.ORCID 0009-0008-5134-1768
Padma Sheila RajagopalCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, University of Chicago, Chicago, Illinois.ORCID 0000-0002-0489-0819
Jeffrey MuellerDepartment of Pathology, University of Chicago, Chicago, Illinois.ORCID 0009-0009-5839-0578
Galina KhramtsovaCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, University of Chicago, Chicago, Illinois.ORCID 0000-0001-9625-1549
Ayodele SanniDepartment of Pathology and Forensic Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.ORCID 0000-0002-7109-8952
Mustapha AjaniDepartment of Pathology, College of Medicine, University of Ibadan/University College Hospital, Ibadan, Oyo, Nigeria.ORCID 0000-0001-5758-5773
Wendy ClaytonCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, University of Chicago, Chicago, Illinois.ORCID 0009-0008-7401-1083
Ian W HurleyCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, University of Chicago, Chicago, Illinois.ORCID 0009-0002-7927-126X
Toshio F YoshimatsuCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, University of Chicago, Chicago, Illinois.ORCID 0000-0003-2674-8159
Yonglan ZhengCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, University of Chicago, Chicago, Illinois.ORCID 0000-0001-6597-7072
Joel ParkerDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0003-2080-6901
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0001-9827-2247
Olufunmilayo I OlopadeCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, University of Chicago, Chicago, Illinois.ORCID 0000-0002-9936-1599
University of Chicago · USUniversity of North Carolina at Chapel Hill · USLagos State University Teaching Hospital · NGUniversity College Hospital, Ibadan · NGUniversity of Illinois Chicago · US

Funding

Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENJAMIN CARLISLE CALHOUN · 1992 to 2026
$59.3M
UChicago Interdisciplinary Cancer Health Disparities SPOREP20CA233307 · NCI · UNIVERSITY OF CHICAGO · PI HUO, DEZHENG · 2018 to 2020
$3.4M
Etiology and Genomics of Breast Cancer Progression in Women of African AncestryR01MD013452 · NIMHD · UNIVERSITY OF CHICAGO · PI HUO, DEZHENG, OLOPADE, OLUFUNMILAYO F. · 2019 to 2023
$2.8M
Identifying Treatment Options using RNA-Based Synthetic Lethality and RescueZIABC012058 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RAJAGOPAL, PADMA · 2021 to 2025
$653k
Development of an integrated prognostic score using common risk variants and RNA-expression data from primary breast cancers for improved prognostication of outcomes across populationsF32CA247244 · NCI · UNIVERSITY OF CHICAGO · PI RAJAGOPAL, PADMA SHEILA · 2020 to 2020
$76k
American Society of Clinical Oncology (ASCO) FP100218Breast Cancer Research Foundation (BCRF) BCRF-20-071Breast Cancer Research Foundation (BCRF) BCRF-22-127Doris Duke Charitable Foundation (DDCF) FP066426NCI NIH HHS F32 CA247244NCI NIH HHS P20 CA233307NCI NIH HHS P50 CA058223NIMHD NIH HHS R01 MD013452Susan G. Komen (SGK) SAC110026Susan G. Komen (SGK) SAC160074Susan G. Komen (SGK) SAC210203
6 · The paper itself

Abstract

purposeBlack women experience the highest breast cancer mortality rate compared with women of other racial/ethnic groups. To gain a deeper understanding of breast cancer heterogeneity across diverse populations, we examined a VEGF-hypoxia gene expression signature in breast tumors from women of diverse ancestry. EXPERIMENTAL

designWe developed a NanoString nCounter gene expression panel and applied it to breast tumors from Nigeria (n = 182) and the University of Chicago (Chicago, IL; n = 161). We also analyzed RNA sequencing data from Nigeria (n = 84) and The Cancer Genome Atlas (TCGA) datasets (n = 863). Patient prognosis was analyzed using multiple datasets.

resultsThe VEGF-hypoxia signature was highest in the basal-like subtype compared with other subtypes, with greater expression in Black women compared with White women. In TCGA dataset, necrotic breast tumors had higher scores for the VEGF-hypoxia signature compared with non-necrosis tumors (P < 0.001), with the highest proportion in the basal-like subtype. Furthermore, necrotic breast tumors have higher scores for the proliferation signature, suggesting an interaction between the VEGF-hypoxia signature, proliferation, and necrosis. T-cell gene expression signatures also correlated with the VEGF-hypoxia signature when testing all tumors in TCGA dataset. Finally, we found a significant association of the VEGF-hypoxia profile with poor outcomes when using all patients in the METABRIC (P < 0.0001) and SCAN-B datasets (P = 0.002).

conclusionsThese data provide further evidence for breast cancer heterogeneity across diverse populations and molecular subtypes. Interventions selectively targeting VEGF-hypoxia and the immune microenvironment have the potential to improve overall survival in aggressive breast cancers that disproportionately impact Black women in the African Diaspora.

Indexed as

Breast NeoplasmsGene Expression Regulation, NeoplasticVascular Endothelial Growth Factor AAdultAgedBiomarkers, TumorBlack or African AmericanBlack PeopleFemaleGene Expression ProfilingHumansHypoxiaMiddle AgedPrognosisTranscriptomeTumor MicroenvironmentBiomarkers, TumorVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID38564595
PMCPMC13015951
OpenAlexW4393715301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.